logo
Could Bringing AI Into the Physical World Make It Profitable?  - What's News

Could Bringing AI Into the Physical World Make It Profitable? - What's News

As businesses are adopting artificial intelligence and beginning to figure out how it will make them money, developers are already working on ways to embody AI in the physical world. From home robots to manufacturing and beyond, tech reporter Belle Lin digs into the industry's plans and tells us whether physical AI might bring both makers and users the big returns on investment they've been anticipating. Alex Ossola hosts.
Full Transcript
This transcript was prepared by a transcription service. This version may not be in its final form and may be updated.
Alex Ossola: Hey, What's News listeners? It's Sunday, June 15th. I'm Alex Ossola for the Wall Street Journal. This is What's News Sunday, the show where we tackle the big questions about the biggest stories in the news by reaching out to our colleagues across the newsroom to help explain what's happening in our world. On today's show, as businesses are finally starting to find ways to integrate artificial intelligence into their operations, developers are already working on future iterations of AI, including ways to embody the technology in the physical world. But the question remains can the developers or companies make money from AI? One of the biggest stories in tech over the past six months is the huge investments tech companies are making in data centers needed to power artificial intelligence. In January, Meta said it was allocating up to $65 billion this year, in the same month, Microsoft committed $80 billion, and in May a data center startup that works with OpenAI secured almost $12 billion. These developers have big plans. They see one of the next steps in artificial intelligence as bringing it out of the cloud and into the physical world like consumer devices and humanoid robots for manufacturing spaces. But will this future phase of AI finally earn a return on investment for these users and developers. To dig more into the AI industry's future plans and whether they'll make AI profitable, I'm joined by Belle Lin who covers AI and enterprise technology for the Journal. Belle, what do developers say is the next phase of AI? What's coming?
Belle Lin: It's an interesting question because it feels like we're still in some of the earliest phases of AI where AI is still chatbots and you have to interact with ChatGPT in order to get something back, you have to type in something. But the wave after chatbots is supposed to be AI agents, and those are technologies or software that can basically do things for you, like order a cab when you're arriving home from the airport or to make a restaurant reservation. And then after that is physical AI and some tech watchers and certainly Jensen Huang, the CEO of Nvidia has talked about this phase as being where AI enters our physical world. And that has a lot of meanings, but in the corporate sense, it can mean that you're bringing automation to warehouses and bringing automation to factories. And then maybe in our daily lives, that's something like bringing humanoid robots to our homes. So broadly it's the idea that AI is entering our devices, whether in our homes, in wearable devices that we wear, or in the factories and the warehouses where our products and goods are made.
Alex Ossola: I'm curious how that actually would work, because right now I think about AI as a chatbot essentially. How does that then become something that is embodied in the physical world, whatever that may mean?
Belle Lin: There are some examples of wearable devices and these AI pins and devices that already came to fruition in this sort of first few phases of AI. There are things like AR and VR goggles that we've all heard of, the Apple Vision Pro. There's the Meta Quest, smart glasses, like from Meta and Snap. And so these are examples of AI that is embedded within these devices that we interact with, usually by voice or with gestures. Sometimes there's a more physical button that we might press or something that we might toggle, but the idea is really that AI gets embedded within the hardware itself rather than the human, the user, us being tied to some screen or some interface that we're used to seeing as a laptop or a phone.
Alex Ossola: Who is leading this trajectory? Who's leading the pack?
Belle Lin: What we've seen from OpenAI and Jony Ive's company is this collaboration called io, in which Jony Ive and his team will serve as the creative brain behind this new device that OpenAI will release, this sort of family of devices. And they've been pretty tight-lipped about what the device will look like and what it will do, but they've said a few things like it'll be ambient, it'll be this third core device that you put on your desk after your MacBook and your iPhone. And so you could say that they're leading the pack because they're promising a lot of what has yet to come, but they have this really great heritage in the whole Apple ecosystem and the design aesthetics that Jony Ive has put out. And also they have the models, they have the fantastic models that OpenAI has pioneered so far that are still state-of-the-art. So when you combine these two technology powerhouses right now, you get a bunch of promises, but they seem pretty promising.
Alex Ossola: It sounds like there are a bunch of different kinds of applications, consumer-facing, more heavy industry, kind of something in between in the form of self-driving cars. Do we have a sense of which of these might sort of come first and how the developers of AI are thinking about monetizing those phases?
Belle Lin: Monetization questions are always front and center because so many of these startups are funded by venture capital firms who need to see a return, and there's so much cash that's being injected into AI right now. Some of the ways in which they're monetizing are in the software side, on the models themselves. So you could sell on a word or a bit basis the ability to use OpenAI's models in other services and other technologies. In the wearable side, the selling of the hardware itself plus the software upgrades. But at this point, it's still really about adoption and figuring out which areas in the consumer world really stick. And then if we're talking about the heavy industry side, that's where ROI becomes a lot more important because you can shave a lot of costs by automating human labor away. And so that's where a lot of the warehouse and logistics companies are hoping to have an impact on their bottom lines.
Alex Ossola: Coming up, AI developers may already be making the next generation of artificial intelligence, but if they build it, will the customers come? Stay with us. Belle, we've been talking a lot about the developer side, how AI gets made and what form it'll be in, but now I want to talk about the people who are going to be buying it and using it. Lots of companies have started using AI. According to a survey by McKinsey, 78% of companies say they use at least one AI function. So it seems like companies need to show they're integrating AI into their operations. Would you say this is an existential need for companies right now?
Belle Lin: Oh, absolutely. There are really existential questions for categories of companies like law firms that have questioned what is the value of the billable hour, because so much of what AI is really good at automating away right now is reading and summarizing through texts and being able to provide synthesis of answers, and that's kind of early stage paralegal work. So if companies don't embrace AI, there's the question of will we still exist in 10 years timeframe? Never mind questions of will we be using AI pins and devices? We need to embrace AI now or else we won't be around.
Alex Ossola: So that kind of brings me back to this other existential question about physical AI. Who actually wants this?
Belle Lin: Well, if you look at examples of where physical AI exists now, I know we've talked about warehouses and factories. But there are also great examples of where wearable headsets like the Apple Vision Pro and the Meta Quest and many others that have been around for a while have huge applications in the military, for instance, for training the armed forces and in training for surgeries and home services where you have skilled trades like plumbers and air conditioning technicians, learning how to build the physical engines that keep homes running as well as jet engines, technicians learning and figuring out how to troubleshoot them. So there's great examples of where physical AI and augmented reality, which is a really early version of bringing AI into the real world, already have a lot of value. And so you might see more acceleration in areas where AI in the real world are already having an impact, but once it becomes much more useful, you could see things like basic knowledge work becoming a lot more augmented because the ability to stream someone's virtual presence into a meeting room makes it that much better and there's no longer a need to have an in-person meeting.
Alex Ossola: One of the things that is in the news cycle about AI right now is just how unbelievably expensive it's been. Companies are shelling out billions of dollars to build these data centers. Because they are doubling down on AI being the future, is there enough demand in all of these different applications for physical AI that we've talked about that will bring down those costs of the data centers or will they just keep skyrocketing?
Belle Lin: A lot of this goes back to the AI models and the software layer because as they become more efficient, then the promise is that they require a lot less GPU compute and power going into the data centers. And so when the models become more efficient themselves, even though they are quite large and unwieldy, they can be trained much more efficiently. From that point of view, costs will certainly start to come down in terms of the infrastructure. But at the same time, other costs will need to come down as well. The cost of hardware in a really general sense is still quite high, the chips required to basically power Apple Vision Pro or to power a humanoid robot or to power self-driving cars, those are not quite commoditized. They're still quite expensive.
Alex Ossola: So as developers make these devices and software and as companies figure out how to use them, whose responsibility is it going to be to figure out how to actually make money off of this?
Belle Lin: Yeah, a lot of the AI developers and the AI startups will be hard-pressed to come up with an answer on how to actually monetize what they're building. Right now, a lot of them are funded by VC dollars, are backed by research or other types of grants and funding. And so there will be this sort of inflection point where either their technologies or their devices, their robots, their cars catch on with consumers or they don't. Because as we look at some of the other waves of technology that were funded by VC dollars, like the Ubers and the Lyfts of the world, there's this limited timeframe in which they can be funded by venture capital dollars until they have to show their metal.
Alex Ossola: And how about for the companies using the products?
Belle Lin: For the companies, that's already a really pressing question. ROI has been challenging since the dawn of the ChatGPT, AI era that we're in now, about three years ago. Companies have been investing heavily in AI models and AI technologies, but there's really not a clear way to determine whether or not they're paying off. So you could say that productivity of workers has gone up, but it's hard to measure. You could say that sales have gone up, but that's also hard to measure. So measuring AI's value has been a question for tech executives for the past several years and continues to be, but there's a lot of economic incentives that are aligned in trying to make sure that the AI companies are profitable and that companies are saving on the bottom line and generating top line revenue that the market forces kind of end up working out in some way.
Alex Ossola: That was WSJ reporter, Belle Lin. Thank you so much, Belle.
Belle Lin: Thanks for having me.
Alex Ossola: And that's it for What's New Sunday for June 15th. Today's show was produced by Charlotte Gartenberg with supervising producer Michael Kosmides and deputy editor Chris Zinsli. I'm Alex Ossola and we'll be back tomorrow morning with a brand new show. Until then, thanks for listening.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

How the Federal Reserve Fuels Fiscal Profligacy
How the Federal Reserve Fuels Fiscal Profligacy

Wall Street Journal

time39 minutes ago

  • Wall Street Journal

How the Federal Reserve Fuels Fiscal Profligacy

If Republicans are serious about reducing federal deficit spending, it is important to consider the effect the Federal Reserve has on the nation's budgetary outlook. If the numerical models imposed by the Congressional Budget Office drive fiscal policy, lawmakers also need to understand what they portend for monetary policy. The Fed once was committed to 'normalizing' its balance sheet—shrinking its footprint in credit markets by reducing the size of its portfolio of Treasury debt and mortgage-backed securities. Chairman Jerome Powell noted in a 2019 speech that large-scale asset purchases by the Fed over the previous 10 years had been viewed from the outset as 'extraordinary measures to be unwound, or 'normalized,' when conditions ultimately warranted.'

Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice
Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice

Yahoo

timean hour ago

  • Yahoo

Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice

Findings highlight the advantages of Adolore's approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediates profound analgesia with the potential to address the great unmet need for non-opioid chronic pain therapies Data further supports the clinical-translational value of Adolore's proprietary non-opioid analgesics for treating chronic non-cancer pain These data support the Company's continuing efforts to progress with IND-enabling studies of ADB-102 gene therapy for the treatment of osteoarthritis (OA) chronic knee pain. DELRAY BEACH, FL / / June 15, 2025 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain and neurological disorders, today announced the publication of its manuscript titled, "Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain Via the Intra-Articular Route in Mice1," in the peer-reviewed journal, Molecular Therapy. Roy Clifford Levitt, MD, Clinical Professor at the University of Miami, Principal Investigator and Program Director of the NIH, NINDS, HEAL Award supporting ADB-102 development for the treatment of chronic knee pain due to OA, and Founder & Executive Chairman of Adolore BioTherapeutics, published biosafety and efficacy data from preclinical studies of Adolore's gene therapy expressing a human carbonic anhydrase-8 variant peptide (CA8*). In model systems, replication-defective, disease-free, herpes simplex virus (rdHSV) gene therapy expressing an analgesic carbonic anhydrase-8 (CA8*) peptide variant corrects somatosensory hyperexcitability by activating Kv7 voltage-gated potassium channels, produces profound, long-lasting analgesia and treats chronic pain from knee OA. In these studies, we provide the first non-Good Laboratory Practices (GLP) biosafety, efficacy, biodistribution, shedding, and histopathology examination of this rdHSV-CA8* via the intra-articular knee route of administration. Naive mice were examined for clinical safety, distribution of virus across all major tissues, knee histopathology, and analgesic efficacy. We observed no signs of persistent toxicity or histopathology, viral genomes remained where they were injected, and there was no evidence of shedding. Profound analgesia persisted for >6 months without functional impairments. These initial biosafety and efficacy data support further development of rdHSV-CA8* for treating chronic knee pain due to moderate-to-severe OA. Dr. Levitt, commented, "Kv7 voltage-gated potassium channel activators, like rdHSV-CA8* open these channels and hyperpolarize nociceptors making them less excitable to produce profound analgesia. Kv7 activators are well-known to produce potent non-opioid-based analgesia in many human chronic pain conditions. While Kv7 openers are no longer available due to off-target adverse events related to systemic administration, they have been successfully translated from animal models to human chronic pain conditions. Bolstered by our substantial body of published data, we continue to develop our innovative approach to address the significant serious unmet need for safe and effective locally acting pain therapies to replace opioids. Our preclinical data strongly support continued preclinical development toward an IND and clinical studies of ADB-102." The Company's lead development program for the treatment of chronic pain in knee osteoarthritis is fully funded by a UG3/UH3 grant awarded to the University of Miami by NIH/NINDS HEAL program to support all formal pre-clinical GLP/GMP/GCP development work through a first-in-human study of ADLR-1l01 in patients expected to commence in 2026. 1 Levitt et al., Biosafety and efficacy of Kv7 activating rdHSV-CA8* analgesic gene therapy for chronic pain via the intraarticular route in mice, Molecular Therapy (2025), About Carbonic Anhydrase-8 (CA8*) Gene Therapy CA8* (variants of naturally occurring human carbonic anhydrase-8 analgesic peptides) gene therapies are a novel class of neuronal calcium channel inhibitors that activate Kv7 voltage-gated potassium channels and are administered locally and long-acting. Oral small molecule pain therapeutics that activate Kv7 voltage-gated potassium channels demonstrated proven analgesic efficacy before they were removed from the market due to severe adverse events related to systemic exposure and their metabolism. CA8* gene therapy provides versatile dosing regimens and routes of administration, including intra-articular, intra-neuronal (nerve block), and intradermal injection. This non-opioid CA8* mechanism-of-action addresses neuropathic, inflammatory, and nociceptive pain, which applies to a broad range of chronic pain indications and neurological disorders. These conditions include osteoarthritis, lower back, and cancer pain; diabetes and other forms of peripheral neuropathy; as well as rare pain conditions such as erythromelalgia, a heritable chronic pain condition and epilepsy and hearing loss. About Adolore BioTherapeutics, Inc. Adolore BioTherapeutics, Inc., is a biotechnology company focused on developing novel therapies for treating chronic pain using a revolutionary intra-cellular replication-defective HSV (rdHSV) drug delivery platform that is disease-free, non-toxic, and permits localized peripheral nervous system delivery of proprietary biotherapeutics. This rdHSV gene therapy technology incorporates an established re-dosing strategy and an excellent safety profile. HSV vectors are known for their stability and prolonged gene expression, providing an excellent basis for the long- term treatment of chronic pain conditions and neurological disorders. Our best-in-class CA8* programs are long-acting, locally administered gene therapies that are opioid-free Disease-Modifying Anti-Pain therapies (DMAPs) designed to treat many forms of chronic pain, epilepsy and hearing loss. Leveraging its innovative gene therapy vectors expressing CA8* analgesic peptides (ADLR-1001), Adolore is currently advancing two preclinical development programs: ADB-101 for the treatment of patients' chronic pain caused by erythromelalgia, an orphan disease, and ADB-102, their lead program for the treatment of patients with chronic pain caused by knee OA. Based on substantial compelling preclinical data generated to date, the Company is progressing these programs toward IND filings and first-in-human clinical studies. Adolore has two additional programs: ADB-104 for Drug-Resistant Refractory Focal Epilepsy and ADB-105 for Acute Severe Hearing Loss. For more information, visit Forward-Looking Statements To the extent, this announcement contains information and statements that are not historical, they are considered forward-looking statements within the meaning of the federal securities laws. You can identify forward-looking statements by the use of the words "believe," "expect," "anticipate," "intend," "estimate," "project," "will," "should," "may," "plan," "intend," "assume" and other expressions which predict or indicate future events and trends and which do not relate to historical matters. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, some of which are beyond the control of the Company. These risks and uncertainties include but are not limited to those associated with drug development. These risks, uncertainties, and other factors may cause the actual results, performance, or achievements of the Company to be materially different from the anticipated future results, performance, or achievements expressed or implied by the forward- looking statements. Investor Relations Contact Paul Barone (215)622-4542pbarone@ SOURCE: Adolore Biotherapeutics, Inc. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Rare earth supply risks: Is Tesla the real target by China?
Rare earth supply risks: Is Tesla the real target by China?

Yahoo

timean hour ago

  • Yahoo

Rare earth supply risks: Is Tesla the real target by China?

-- With China granting rare earth export licenses to GM, Ford, and Stellantis (NYSE:STLA) but not to Tesla (NASDAQ:TSLA), questions are mounting over whether Tesla is being deliberately targeted amid ongoing trade tensions and Musk's outspoken foreign policy stance. 'Media reports only indicate GM, F & STLA received licenses. This implies TSLA & RIVN could still be waiting for licenses. It's possible this is the consequence of Musk's aggressive stance on foreign policy & China's aim to support local EV makers,' Wells Fargo wrote, citing expert Dr. Gracelin Baskaran. China controls nearly 100% of global supply for the seven most critical heavy rare earth elements, or REEs, which are essential for electric vehicle motors and other advanced manufacturing. The U.S. auto sector is the largest end-user of these materials, but America's consumption is a fraction of global output—just 6,600 tonnes out of 390,000 tonnes produced last year. Following China's April 4 restrictions, automakers had only 2-3 months of buffer stock, and those reserves are now running low. While the six-month licenses keep operations running for some U.S. automakers, Wells Fargo warns the current arrangement is 'still a band-aid, not a fix,' with supply risks likely to persist for another two to five years as new capacity ramps up outside China. For now, China's selectivity in granting licenses and vigilance over end-use means Tesla—and other OEMs still waiting—could face mounting pressure until global rare earth supply chains diversify. Related articles Rare earth supply risks: Is Tesla the real target by China? 2025 Global Technology Conference: What did we learn? Has AI started replacing junior software developers? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store